Here are three reasons why there are better opportunities than TXG and a stock we'd rather own. Founded in 2012, 10x Genomics (NASDAQ:TXG) develops single-cell and spatial genomics solutions ...

Serge Saxonov, the Chief Executive Officer of $TXG, sold 7,942 shares of the company on 02-28-2025 for an estimated $84,393. We received data on the trade from a ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full ...

10x Genomics (NASDAQ:TXG) just reported results for the first quarter of 2024. 10x Genomics reported earnings per share of -50 cents. This met the analyst estimate for EPS of -50 cents.

10x Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences. On February 25, 2025, a consent agreement ...

10x Genomics Price Performance Shares of TXG opened at $12.31 on Tuesday. The firm has a market cap of $1.49 billion, a PE ratio of -8.05 and a beta of 1.85. The stock’s fifty day moving average ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...